Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma

NCT02884453 is registered in ClinicalTrials.gov with Royal Marsden NHS Foundation Trust as lead sponsor.

NCT NCT02884453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02884453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma
Lead sponsor
Royal Marsden NHS Foundation Trust
Phase
Phase 2
Overall status
Unknown status
Start date
July 19, 2016
Completion date
December 30, 2021
Enrollment
17 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastrooesophageal cancer